Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot
Completed · Phase 1
Conditions studied: Acute Heart Failure
In brief
The Pilot study is designed to evaluate the overall safety and feasibility of a strategy based on subcutaneous delivery of furosemide. It will be used to inform the subsequent evaluation phase of the study (separate protocol). The primary objective of the study is to determine if a strategy of a novel subcutaneous delivery of furosemide is safe and feasible in patients with acute heart failure.
Key facts
- Study ID
- NCT02877095
- Run by
- Adrian Hernandez
- People needed
- 40
- Starts
- 2016-12-19
- Expected to finish
- 2017-11-07
- Last updated by the study team
- 2019-03-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age >18 years
- Willingness and ability to provide informed consent
- Hospitalization for acute heart failure (AHF) with at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography, Brain Natriuretic Peptide > 250 ng/mL or N-terminal pro-brain natriuretic peptide (NTproBNP) > 1000 ng/mL) of congestion
- Persistent congestion despite at least 18 hours of intravenous (IV) therapy, defined by the presence of at least 2 or more of the following at the time of consent:
- Peripheral edema
- Rales
- Elevated jugular venous pressure (JVP)
- Ascites
- BNP > 250 ng/mL or NTproBNP > 1000 ng/mL
- Total anticipated daily IV furosemide dose (at time of screening) >80-200 mg (or equivalent)/day
- Anticipated need for at least 24 more hours of parenteral diuretic therapy -
You may not qualify if…
- Severe renal dysfunction (Estimated Glomerular Filtration Rate (eGFR)< 30 ml/min/1.73m2)
- Requirement for inotropes (other than digoxin) or mechanical support during hospitalization
- Clinically significant electrical instability during hospitalization
- Ongoing need for other intravenous therapies beyond diuretics (vasodilators, antibiotics, etc.)
- Anticipated need for ongoing parenteral electrolyte repletion
- Planned discharge to location other than home (e.g, hospice, skilled nursing facility, etc.)
- Anticipated cardiac transplantation or left ventricular assist device within the next 30 days
- Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade
- Known or anticipated pregnancy in the next 30 days Prior use of subcutaneous furosemide pump or current use of any subcutaneous pump, on-body infusion devices or patients who give regimented injections at the intended site of the furosemide infusion device
- Other psychosocial or physical barriers to following the protocol and using a subcutaneous pump device outside the hospital setting
- Unable to accurately measure urine output
- Known allergy to furosemide
- Known sensitivity or allergy to medical adhesive tape
Where it is running
- Emory University Hospital — Atlanta, Georgia, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Metro Health System — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.